Imagen de Portada

Iron overload is closely associated with metabolic dysfunction‐associated fatty liver disease in type 2 diabetes

Fuente: Wiley Open Access

Guardado en:

Detalles Bibliográficos
Autores principales:	Huanjia Qu, Lingling Zhou, Jing Wang, Dong Tang, Qiuling Zhang, Junping Shi
Formato:	Artículo Open Access
Publicado:	Wiley 2025
Materias:	Obesity
Acceso en línea:	Acceder al recurso
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Long‐term outcomes of metabolic surgery versus medical/lifestyle therapy on metabolic dysfunction‐associated fatty liver disease in adults with obesity and type 2 diabetes
por: Michelle D. Lundholm, et al.
Publicado: (2024)

An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
por: Zhuolin Zhou, et al.
Publicado: (2025)

Associations between cuprotosis‐related genes and the spectrum of metabolic dysfunction‐associated fatty liver disease: An exploratory study
por: Hai‐Yang Yuan, et al.
Publicado: (2024)

Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
por: Claudio Maffeis, et al.
Publicado: (2024)

Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
por: Wenxiao Fan, et al.
Publicado: (2025)

Metabolic dysfunction‐associated steatotic liver disease is associated with worse time in ranges in type 1 diabetes
por: Chloë Aernouts, et al.
Publicado: (2024)

Serum bile acid profiles are associated with heart failure with preserved ejection fraction in patients with metabolic dysfunction‐associated fatty liver disease: An exploratory study
por: Xiao‐Dong Zhou, et al.
Publicado: (2024)

Reduced insulin clearance in paediatric metabolic (dysfunction)‐associated fatty liver disease and its dual role in beta‐cell offload and diabetes risk
por: Li Jiang, et al.
Publicado: (2024)

The association of ultra‐processed food intake with adolescent metabolic dysfunction‐associated steatotic liver disease in the NHANES
por: Maarten Buytaert, et al.
Publicado: (2024)

Therapeutic potential of stem cell‐derived somatic cells to treat metabolic dysfunction‐associated steatotic liver disease and diabetes
por: Eduardo H. Gilglioni, et al.
Publicado: (2025)

High‐intensity interval training induces lactate dehydrogenase B lactylation to inhibit hepatic lipogenesis to alleviate metabolic dysfunction‐associated fatty liver disease
por: Wenhua Huang, et al.
Publicado: (2026)

The correlation of apolipoprotein B and apolipoprotein A1 with metabolic dysfunction‐associated steatotic liver disease in children and adolescents with obesity
por: Xiao‐Yan Shi, et al.
Publicado: (2025)

Causal relationship between key genes and metabolic dysfunction‐associated fatty liver disease risk mediated by immune cells: A Mendelian randomization and mediation analysis
por: Gong Feng, et al.
Publicado: (2024)

G3BP1 , a stress granule core protein, ameliorates metabolic dysfunction‐associated fatty liver disease by attenuating hepatocyte lipid deposition
por: Xingjing Liu, et al.
Publicado: (2025)

Food insecurity is a risk factor for metabolic dysfunction‐associated steatotic liver disease in Latinx children
por: Sarah L. Maxwell, et al.
Publicado: (2024)

Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
por: Yuqing Ma, et al.
Publicado: (2025)

Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes
por: Sarra Smati, et al.
Publicado: (2024)

Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors and dipeptidyl peptidase‐4 inhibitors in improvement of fatty liver index in patients with type 2 diabetes mellitus and metabolic dysfunction‐associated steatotic liver disease: A retrospective nationwide claims database study in Japan
por: Mitsuhiro Shikamura, et al.
Publicado: (2024)

Oxidized high‐density lipoprotein and low‐density lipoprotein in adolescents with obesity and metabolic dysfunction‐associated steatotic liver disease
por: Alyssa M. Bartlett, et al.
Publicado: (2024)

Metabolic dysfunction‐associated steatotic liver disease and cancer risk: A cohort study
por: Yu Peng, et al.
Publicado: (2025)

Letter to the Editor to “ G3BP1 , a stress granule core protein, ameliorates metabolic dysfunction‐associated fatty liver disease by attenuating hepatocyte lipid deposition”
por: Cyril Sobolewski, et al.
Publicado: (2025)

Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies
por: Seoung Hoon Kim
Publicado: (2026)

The prognostic value of metabolic dysfunction‐associated steatotic liver disease in acute myocardial infarction: A propensity score‐matched analysis
por: Gwyneth Kong, et al.
Publicado: (2024)

Sodium‐glucose co‐transporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors on major liver outcomes in metabolic dysfunction‐associated steatotic liver disease
por: Tsung‐Hua Shen, et al.
Publicado: (2024)

The depletion of serine beta‐lactamase‐like protein (LACTB) ameliorates metabolic dysfunction–associated steatotic liver disease by reducing ubiquitin‐mediated degradation of carnitine palmitoyltransferase 2
por: Wujiang Shi, et al.
Publicado: (2026)

Association of overweight/obesity and overweight/obesity‐related metabolic dysfunction‐associated steatotic liver disease in young adults with coronary artery calcification later in life
por: Jia‐Jie Wang, et al.
Publicado: (2024)

Hepatic steatosis index for prediction of metabolic dysfunction‐associated steatotic liver disease ( MASLD ) among young Indian women with gestational diabetes and normoglycaemia during index pregnancy
por: Alpesh Goyal, et al.
Publicado: (2025)

Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction‐associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta‐analysis
por: Jiaxin Zhong, et al.
Publicado: (2025)

Impact of healthy lifestyles on the risk of metabolic dysfunction‐associated steatotic liver disease among adults with comorbid hypertension and diabetes: Novel insight from a largely middle‐aged and elderly cohort in South China
por: Jun‐Yan Xi, et al.
Publicado: (2025)

Modelling and assessment of glucose‐lactate kinetics in youth with overweight, obesity and metabolic dysfunction‐associated steatotic liver disease: A pilot study
por: Jacopo Bonet, et al.
Publicado: (2024)

Gamma‐glutamyl transferase: A potential biomarker for pancreas steatosis in patients with concurrent obesity, insulin resistance and metabolic dysfunction‐associated steatotic liver disease
por: Chileka Chiyanika, et al.
Publicado: (2024)

Similar weight loss with semaglutide regardless of diabetes and cardiometabolic risk parameters in individuals with metabolic dysfunction‐associated steatotic liver disease: Post hoc analysis of three randomised controlled trials
por: Matthew J. Armstrong, et al.
Publicado: (2024)

Metabolic dysfunction‐associated steatotic liver disease, insulin sensitivity and continuous glucose monitoring metrics in patients with type 1 diabetes: A multi‐centre cross‐sectional study
por: Michela Vergani, et al.
Publicado: (2025)

Impact of non‐alcoholic fatty liver disease and fibrosis on mortality and kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A multi‐cohort longitudinal study
por: Lijun Zhao, et al.
Publicado: (2024)

Diagnostic accuracy of Agile‐4 score for liver cirrhosis in patients with metabolic dysfunction‐associated steatotic liver disease. A systematic review and meta‐analysis of diagnostic test accuracy studies
por: Konstantinos Malandris, et al.
Publicado: (2024)

A review of multidisciplinary care in metabolic dysfunction‐associated steatohepatitis and cardiometabolic disease, with a focus on Canada
por: James Kim, et al.
Publicado: (2025)

Efficacy and safety of liraglutide in non‐alcoholic fatty liver disease with or without type 2 diabetes: A systematic review and meta‐analysis
por: Weihan Kong, et al.
Publicado: (2025)

Is the combination of resmetirom and semaglutide useful for the treatment of metabolic dysfunction‐associated steatohepatitis?
por: Stergios A. Polyzos, et al.
Publicado: (2026)

Body weight variability and the risk of liver‐related outcomes in type 2 diabetes and steatotic liver disease: a cohort study
por: Nathalie C. Leite, et al.
Publicado: (2024)

Long‐term all‐cause mortality of metabolic‐dysfunction associated steatotic liver disease based on body weight phenotypes following acute myocardial infarction: A retrospective cohort study
por: Jaycie Koh, et al.
Publicado: (2024)